Wikipedia -WSS

Wikipedia

author：comprehensive 2025-09-29 01:37:03 - browse：9

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter:

Novo Nordiskis conducting a large clinical trial to prove that its GLP-1 drug Wegovy, in addition to helping people lose weight, also improves cardiovascular health. The SELECT study enrolled 17,500 participants who had overweight or obesity and had preexisting heart disease. The participants were then randomized to receive weekly injections of Wegovy or a matching placebo. The primary goal is to determine the extent to which Wegovy reduces the risk of heart attacks, strokes, and heart-related deaths. Wegovy is already a blockbuster drug based on weight loss alone, but proving an additional cardiovascular benefit could open the commercial floodgates.

BridgeBiowill report in July an analysis of all-cause mortality from a clinical trial of its heart drug acoramidis. The outcome is an important, second attempt at demonstrating benefit for acoramidis in a progressive heart disease called ATTR-CM. In December 2021, the drug performed no better than a placebo on a test of how far study participants could walk over the course of six minutes, failing to achieve its primary goal. But in this second part of the same study, BridgeBio will determine if acoramidis can significantly reduce hospitalizations and death over the course of 30 months.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： STAT Summit: How a Chicago ER doctor tackles gun violence

explore

entertainment

WSS

FDA gives detailed accounting of AI

STAT Summit: GSK CEO on pharma giant's new direction

Slovenia has suffered its worst

STAT Summit: GSK CEO on pharma giant's new direction

Tuberculosis patients need more than just free medication

The explosion of genetic testing requires a new approach

focus

Wikipedia

focus

In age of alternative facts, a scholarly course on calling out crap

FDA gives detailed accounting of AI

Moonlake's readout produced a cash windfall. Risks remain

Doctors push to include dialysis machines in emergency stockpile

United colonoscopy coverage change 'may cost lives,' doctors say

Solve the antibiotic resistance crisis with preventive drugs

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Pharmacists can make shortage drugs, but at what cost?

Trump demands the U.S. pay no more for drugs than other countries … again

UnitedHealth’s board chair also owns a personal investment firm

entertainment

STAT Summit: Michael J. Fox on progress in Parkinson's research

Trump used to be more articulate. What could explain the change?

Hospital price transparency does save money, advocate argues

It was time to plan for my old age. If only I could stop crying

Impact of Dobbs ruling felt at reproductive medicine meeting

Senate committee scrutinizes Medicare Advantage brokers

focus

explore

entertainment

leisure time